Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dor BioPharma, a late-stage biopharmaceutical company, has appointed Gregg Lapointe to its board of directors.
Subscribe to our email newsletter
Mr Lapointe is currently CEO of Sigma-Tau Pharmaceuticals, a company engaged in the development and commercialization of medicines for patients with rare diseases. Sigma-Tau is Dor’s North American partner for orBec and its largest shareholder.
Mr Lapointe has served in various roles for Sigma-Tau since 2001, including COO from November 2003 to April 2008 and CEO since April 2008. Prior to Sigma-Tau, he served as vice president of operations and vice president, controller of AstenJohnson (formerly JWI).
Christopher Schaber, president and CEO of Dor, said: “We are very pleased to welcome Gregg Lapointe to our board of directors. Mr Lapointe brings extensive experience in the areas of global strategic planning and implementation, corporate finance, accounting, and acquisitions.
“With his strong business and healthcare background, he is well positioned to make significant contributions to the continued growth and success of Dor. We are enthusiastically looking forward to his productive involvement on our board.”